Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive care in older patients with advanced MDS

Share :
Published: 17 Feb 2021
Views: 468
Dr Ryotaro Nakamura - City of Hope, California, USA

Dr Ryotaro Nakamura speaks to ecancer about a multi-centre biologic assignment trial comparing reduced intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients aged 50-75 with advanced myelodysplastic syndrome: blood and marrow transplant clinical trials network study.

This study was presented at ASH 2020 virtual conference.

Dr Nakamura initially speaks about the rationale behind the study and the method in which this study was conducted.

He then explains some of the key results from this study and talks about the future impact that these results can have on the treatment of patients with advanced myelodysplastic syndrome.